Company Filing History:
Years Active: 2002
Title: Ernst Reichmann: Innovator in Pharmaceutical Research
Introduction
Ernst Reichmann is a notable inventor based in Epalinges, Switzerland. He has made significant contributions to the field of pharmaceutical research, particularly in the treatment of tumor diseases. His innovative work has led to the development of methods that could potentially revolutionize cancer treatment.
Latest Patents
Reichmann holds a patent for "Methods of screening for pharmacologically active compounds for the treatment of tumour diseases." This patent focuses on pharmaceutical compositions that contain a substance which inhibits the activity of TGFβ on tumor cells of epithelial origin. The invention aims to treat epithelial, invasive tumor diseases characterized by a reversible transition of cells from an epithelial, non-invasive state into a fibroblastoid, invasive state. The pharmaceutical composition includes a TGFβ inhibitor, preferably combined with an Ras inhibitor, and outlines a process for screening substances for the treatment of these diseases. He has 1 patent to his name.
Career Highlights
Reichmann is associated with Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His work there has been instrumental in advancing research and development in oncology. His innovative approaches have garnered attention in the scientific community.
Collaborations
Throughout his career, Reichmann has collaborated with esteemed colleagues such as Hartmut Beug and Martin Oft. These partnerships have further enriched his research and contributed to the advancement of pharmaceutical sciences.
Conclusion
Ernst Reichmann's contributions to pharmaceutical research, particularly in the treatment of tumor diseases, highlight his role as an influential inventor. His innovative methods and collaborations continue to pave the way for advancements in cancer treatment.